These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10492157)

  • 1. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells.
    Ohara T; Arakawa T
    Dig Dis Sci; 1999 Aug; 44(8):1710-5. PubMed ID: 10492157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
    Yoshida N; Yoshikawa T; Tanaka Y; Fujita N; Kassai K; Naito Y; Kondo M
    Aliment Pharmacol Ther; 2000 Apr; 14 Suppl 1():74-81. PubMed ID: 10807407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of mononuclear cells.
    Peddicord TE; Olsen KM; Collier DS
    Crit Care Med; 1999 Jan; 27(1):90-4. PubMed ID: 9934899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
    Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
    Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
    J Clin Gastroenterol; 1995; 20 Suppl 2():S1-135. PubMed ID: 7594319
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
    Morozov IA
    Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.
    Rizzo N; Padoin C; Palombo S; Scherrmann JM; Girre C
    Eur J Clin Pharmacol; 1996; 49(6):491-5. PubMed ID: 8706775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
    Altintas E; Sezgin O; Ulu O; Aydin O; Camdeviren H
    World J Gastroenterol; 2004 Jun; 10(11):1656-8. PubMed ID: 15162544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate.
    Coruzzi G; Coppelli G; Frati P; Bertaccini G
    Pharmacol Res; 1998 Dec; 38(6):469-73. PubMed ID: 9990656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
    Jhala NC; McFarland MM; Brightman SA; Morale B; Rubin W; Atkinson BF
    Am J Gastroenterol; 1995 Oct; 90(10):1824-8. PubMed ID: 7572902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
    Hawkey CJ; Long RG; Bardhan KD; Wormsley KG; Cochran KM; Christian J; Moules IK
    Gut; 1993 Oct; 34(10):1458-62. PubMed ID: 8244121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
    Malizia T; Tejada M; Marchetti F; Favini P; Pizzarelli G; Campa M; Senesi S
    J Antimicrob Chemother; 1998 Mar; 41 Suppl B():29-35. PubMed ID: 9579710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.